NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: drug costs


Gene therapy and hemophilia: Washington Post wisely tells readers ‘the study has some limitations’

1 10/21/2016

Are expensive, potent anti-inflammatory drugs a future option for depression? CNN’s story needed more scrutiny of evidence


False balance in CNN coverage of female sexual dysfunction: anecdotes given equal weight as systematic evidence review


Interesting but evidence-free story on ibuprofen skin patch


A gloss over costs in coverage of competing blood pressure meds — but also some strengths

1 11/13/2015

WSJ whiffs on meaningful aspects of new melanoma drug approval — including $17,600/month price tag

2 10/29/2015

Thorough look at underuse of long-term reversible contraceptives

1 9/28/2015

With just 226 words, NYT can’t deliver needed context on Alzheimer’s agitation study


Story on new melanoma drug combo neglects to mention $250,000 price tag